Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Brian Boyarsky and William Werbel.
Connection Strength

5.872
  1. SARS-CoV-2 Messenger RNA Vaccine Immunogenicity in Solid Organ Transplant Recipients With Prior COVID-19. Transplantation. 2021 11 01; 105(11):e270-e271.
    View in: PubMed
    Score: 0.976
  2. Antibody Kinetics and Durability in SARS-CoV-2 mRNA Vaccinated Solid Organ Transplant Recipients. Transplantation. 2021 10 01; 105(10):e137-e138.
    View in: PubMed
    Score: 0.971
  3. Antibody Response to a Fourth Dose of a SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series. Transplantation. 2021 12 01; 105(12):e280-e281.
    View in: PubMed
    Score: 0.245
  4. Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in persons with HIV. AIDS. 2021 11 15; 35(14):2399-2401.
    View in: PubMed
    Score: 0.245
  5. Antibody Response to the Janssen COVID-19 Vaccine in Solid Organ Transplant Recipients. Transplantation. 2021 08 01; 105(8):e82-e83.
    View in: PubMed
    Score: 0.240
  6. Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series. Ann Intern Med. 2021 09; 174(9):1330-1332.
    View in: PubMed
    Score: 0.238
  7. Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients. JAMA. 2021 06 01; 325(21):2204-2206.
    View in: PubMed
    Score: 0.237
  8. Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients. JAMA. 2021 05 04; 325(17):1784-1786.
    View in: PubMed
    Score: 0.236
  9. Safety of the First Dose of SARS-CoV-2 Vaccination in Solid Organ Transplant Recipients. Transplantation. 2021 05 01; 105(5):e56-e57.
    View in: PubMed
    Score: 0.236
  10. Early Development and Durability of SARS-CoV-2 Antibodies Among Solid Organ Transplant Recipients: A Pilot Study. Transplantation. 2021 05 01; 105(5):e52-e53.
    View in: PubMed
    Score: 0.236
  11. Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases. Ann Rheum Dis. 2021 Mar 23.
    View in: PubMed
    Score: 0.234
  12. Evolving Impact of COVID-19 on Transplant Center Practices and Policies in the United States. Clin Transplant. 2020 12; 34(12):e14086.
    View in: PubMed
    Score: 0.226
  13. Early national and center-level changes to kidney transplantation in the United States during the COVID-19 epidemic. Am J Transplant. 2020 11; 20(11):3131-3139.
    View in: PubMed
    Score: 0.224
  14. Early Experiences With COVID-19 Testing in Transplantation. Transplant Direct. 2020 Jul; 6(7):e572.
    View in: PubMed
    Score: 0.222
  15. Early impact of COVID-19 on transplant center practices and policies in the United States. Am J Transplant. 2020 07; 20(7):1809-1818.
    View in: PubMed
    Score: 0.220
  16. Disease Flare and Reactogenicity in Patients With Rheumatic and Musculoskeletal Diseases Following Two-Dose SARS-CoV-2 Messenger RNA Vaccination. Arthritis Rheumatol. 2022 01; 74(1):28-32.
    View in: PubMed
    Score: 0.061
  17. Safety and Reactogenicity of 2 Doses of SARS-CoV-2 Vaccination in Solid Organ Transplant Recipients. Transplantation. 2021 10 01; 105(10):2170-2174.
    View in: PubMed
    Score: 0.061
  18. Antibody Response to Severe Acute Respiratory Syndrome-Coronavirus-2 Messenger RNA Vaccines in Liver Transplant Recipients. Liver Transpl. 2021 12; 27(12):1852-1856.
    View in: PubMed
    Score: 0.060
  19. Safety and antibody response to the first dose of severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine in persons with HIV. AIDS. 2021 09 01; 35(11):1872-1874.
    View in: PubMed
    Score: 0.060
  20. Immunogenicity and Reactogenicity After SARS-CoV-2 mRNA Vaccination in Kidney Transplant Recipients Taking Belatacept. Transplantation. 2021 09 01; 105(9):2119-2123.
    View in: PubMed
    Score: 0.060
  21. Antibody response to the Janssen/Johnson & Johnson SARS-CoV-2 vaccine in patients with rheumatic and musculoskeletal diseases. Ann Rheum Dis. 2021 10; 80(10):1365-1366.
    View in: PubMed
    Score: 0.060
  22. SARS-CoV-2 messenger RNA vaccine antibody response and reactogenicity in heart and lung transplant recipients. J Heart Lung Transplant. 2021 12; 40(12):1579-1588.
    View in: PubMed
    Score: 0.060
  23. Kidney Transplant Recipient Attitudes Toward a SARS-CoV-2 Vaccine. Transplant Direct. 2021 Jul; 7(7):e713.
    View in: PubMed
    Score: 0.059
  24. Absence of Humoral Response After Two-Dose SARS-CoV-2 Messenger RNA Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: A Case Series. Ann Intern Med. 2021 09; 174(9):1332-1334.
    View in: PubMed
    Score: 0.059
  25. High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases. Ann Rheum Dis. 2021 10; 80(10):1351-1352.
    View in: PubMed
    Score: 0.059
  26. Safety of the first dose of mRNA SARS-CoV-2 vaccines in patients with rheumatic and musculoskeletal diseases. Ann Rheum Dis. 2021 Mar 19.
    View in: PubMed
    Score: 0.058
  27. Incidence and Outcomes of COVID-19 in Kidney and Liver Transplant Recipients With HIV: Report From the National HOPE in Action Consortium. Transplantation. 2021 01 01; 105(1):216-224.
    View in: PubMed
    Score: 0.058
  28. Liver transplantation in the United States during the COVID-19 pandemic: National and center-level responses. Am J Transplant. 2021 05; 21(5):1838-1847.
    View in: PubMed
    Score: 0.057
  29. Effects of COVID-19 pandemic on pediatric kidney transplant in the United States. Pediatr Nephrol. 2021 01; 36(1):143-151.
    View in: PubMed
    Score: 0.057
  30. Identifying scenarios of benefit or harm from kidney transplantation during the COVID-19 pandemic: A stochastic simulation and machine learning study. Am J Transplant. 2020 11; 20(11):2997-3007.
    View in: PubMed
    Score: 0.056
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.